Applied Therapeutics, Inc. (APLT) Insider Trading Activity

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Show less

Over the last 12 months, insiders at Applied Therapeutics, Inc. have bought $undefined and sold $undefined worth of Applied Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Applied Therapeutics, Inc. have bought $2.47M and sold $2.75M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 30,000 shares for transaction amount of $65,367 was made by Kanter Stacy J. (director) on 2023‑12‑01.